MedPath

Determine Long-Term Safety and Tolerability of Pregabalin in Patients With Anxiety Disorders.

Phase 3
Completed
Conditions
Anxiety Neuroses
Registration Number
NCT00150449
Lead Sponsor
Pfizer
Brief Summary

Determine long-term safety and tolerability of pregabalin in patients with anxiety disorders.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
511
Inclusion Criteria
  • Must have completed the double-blind portion of the preceding trial
  • Completed any protocol specified withdrawal phase and follow-up visits.
Read More
Exclusion Criteria
  • Patient cannot participate if they experienced a serious adverse event or a nonserious, but medically significant adverse event during the preceding efficacy study that was judged to be related to the study medication.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Safety Tolerability
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Pfizer Investigational Site

© Copyright 2025. All Rights Reserved by MedPath